Accepted for presentation at The Triological Society Combined Section Meeting, Marco Island, Florida, U.S.A., February 14–18, 2007.
The Skin Cancer Index: Clinical Responsiveness and Predictors of Quality of Life†
Article first published online: 2 JAN 2009
Copyright © 2007 The Triological Society
Volume 117, Issue 3, pages 399–405, March 2007
How to Cite
Rhee, J. S., Matthews, B. A., Neuburg, M., Logan, B. R., Burzynski, M. and Nattinger, A. B. (2007), The Skin Cancer Index: Clinical Responsiveness and Predictors of Quality of Life. The Laryngoscope, 117: 399–405. doi: 10.1097/MLG.0b013e31802e2d88
This research was in part funded by an educational grant from the American Society for Dermatologic Surgery and the National Institutes of Health/National Cancer Institute R03 CA108271.
- Issue published online: 2 JAN 2009
- Article first published online: 2 JAN 2009
- Manuscript Accepted: 6 NOV 2006
- Skin cancer;
- quality of life;
- basal cell cancer;
- squamous cell cancer
Objective: To establish the clinical responsiveness of the Skin Cancer Index (SCI), a new disease-specific quality of life (QOL) instrument, and to assess demographic and clinical factors which impact QOL in patients with nonmelanoma skin cancer (NMSC).
Study Design: Prospective study of 183 patients with NMSC of the face and neck referred to a tertiary care Mohs surgery clinic.
Methods: The SCI is a 15 item, validated, disease-specific QOL instrument with 3 distinct subscales, Emotion, Social, and Appearance. Higher scores reflect better QOL. The SCI and the Dermatology Life Quality Index (DLQI), a general dermatology instrument, was administered at initial consultation and 4 months after surgical treatment. Multivariate analysis was conducted to assess demographic and clinical factors predictive of QOL for both instruments.
Results: The SCI total score and all three subscale scores increased with treatment, demonstrating strong evidence of responsiveness over time (P < .001) in contrast with the DLQI (P = .46). Predictors of poorer QOL for the SCI included female sex and cancers located on the lip. Patients who demonstrated greatest improvement in QOL with treatment included those who were younger (<50 yr) and had lower reported household income. Also, first time NMSC patients and those patients who underwent less extensive reconstructions demonstrated greater improvements in QOL.
Conclusion: The SCI is a sensitive and responsive QOL instrument for patients with NMSC. Distinct demographic and clinical variables that impact QOL have been demonstrated using this multidimensional, disease-specific instrument.